Drug Profile
Affitope AD01
Alternative Names: AD 01 - AFFiRiS; AD-1; Alzheimer AD01Latest Information Update: 25 Nov 2009
Price :
$50
*
At a glance
- Originator AFFiRiS
- Class Alzheimer vaccines; Antidementias
- Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Alzheimer's disease
Most Recent Events
- 19 Nov 2009 Suspended - Phase-I for Alzheimer's disease in Austria (SC)
- 20 Oct 2009 A phase I trial met its primary endpoint of safety and tolerability in patients with Alzheimer's disease
- 16 Sep 2009 Interim adverse events data from phase I trials in Alzheimer's disease presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP-2009)